WO2002009712A1 - Utilisation de derives de quinolein-2(1h)-one pour le traitement de l'insuffisance renale - Google Patents
Utilisation de derives de quinolein-2(1h)-one pour le traitement de l'insuffisance renale Download PDFInfo
- Publication number
- WO2002009712A1 WO2002009712A1 PCT/FR2001/002493 FR0102493W WO0209712A1 WO 2002009712 A1 WO2002009712 A1 WO 2002009712A1 FR 0102493 W FR0102493 W FR 0102493W WO 0209712 A1 WO0209712 A1 WO 0209712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pharmaceutically acceptable
- treatment
- acceptable salts
- preparation
- Prior art date
Links
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 208000017169 kidney disease Diseases 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims description 20
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 8
- 201000006370 kidney failure Diseases 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- -1 4- (thieno [3,2-c] pyridin-4-yl) piperazin-1-yl Chemical group 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 239000002775 capsule Substances 0.000 description 5
- 108010061435 Enalapril Proteins 0.000 description 4
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 4
- 229960000873 enalapril Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000885 nephron Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- CXTAICCBLKFYHQ-UHFFFAOYSA-N 7-fluoro-4-[2-(4-thieno[3,2-c]pyridin-4-ylpiperazin-1-yl)ethyl]-1h-quinolin-2-one Chemical compound C=1C(=O)NC2=CC(F)=CC=C2C=1CCN(CC1)CCN1C1=NC=CC2=C1C=CS2 CXTAICCBLKFYHQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- GUCOHALGSMFJNM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)acetamide Chemical compound C1=CC=C2N(CC(=O)N)CC=CC2=C1 GUCOHALGSMFJNM-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Definitions
- the subject of the present invention is the use of quinoline-2 (1H) -one derivatives or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended for the treatment of renal failure.
- Quinolin-2 (1H) -one derivatives or their pharmaceutically acceptable salts are described in European patent EP 850235. They can find therapeutic applications, as described in the European patent mentioned above, in the treatment and prevention of various pathological forms involving serotonin, such as arterial, venous, pulmonary, portal, renal or ocular hypertension, cardiac, renal, ocular, cerebral or lower extremity ischemia, heart failure, myocardial infarction, angina , coronary or peripheral vasospasms, thrombosis, arteritis, intermittent claudication, restenosis after angioplasty and various pathological conditions associated with atherosclerosis, microcirculation disorders or pulmonary dysfunctions.
- pathological forms involving serotonin such as arterial, venous, pulmonary, portal, renal or ocular hypertension, cardiac, renal, ocular, cerebral or lower extremity ischemia, heart failure, myocardial infarction, angina , coronary or peripheral vasospasms, thrombosis,
- A represents either a 4- (thieno [3,2-c] pyridin-4-yl) piperazin-1-yl group, or a 4- (4-fluorobenzoyl) pifughdin-1-yl group,
- R- and R 2 each independently of one another represent a hydrogen atom, a halogen atom, an amino group, a hydroxy group, a nitro group, or a cyano group, or a (dC 6 ) alkyl group, or a (C 1 -C 6 ) alkoxy group, or a trifluoromethyl group, or a group trifluoromethoxy, either a -COOH group, or a -COOR 4 group, or a -CONH 2 group, or a -CONHR 4 group, or a -CONR ⁇ s group, or a -SR 4 group, or a -SO 2 group R 4 , either a group -NHCOR 4 , or a group -NHSO ⁇ , or a group -N (R 4 ) 2 where R 4 and R 5 are each an (C 1 -C 4 ) alkyl group,
- R 3 represents either a hydrogen atom, or a (C 1 -C 4 ) alkyl group, or a group - (CH 2 ) p OH, or a group - (CH 2 ) p NH 2t or a group - (CH 2 ) n COOH, either a group - (CH 2 ) n COOR 4 , or a group - (CH 2 ) n CONH 2 , or a group - (CH 2 ) n CONHOH, or a group - (CH 2 ) P SH , either a group - (CH 2 ) n SO 3 H, or a group - (CH 2 ) n SO 2 NH 2 , or a group - (CH 2 ) n SO 2 NHR 4 , or a group - (CH 2 ) n SO 2 NR 4 R 5 , either a group - (CH 2 ) n CONHR, or a group - (CH ⁇ CONR ⁇ s
- R 4 and R 5 are each an (C 1 -C 4 ) alkyl group, n is equal to 1, 2, 3 or 4, p is equal to 2, 3 or 4 and m is 2, 3 or 4.
- quinoline-2 (1H) -one derivatives of formula (I), as well as their pharmaceutically acceptable salts, in particular 7-fluoro-2-oxo-4- [2- [4 - (thieno [3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl] 1,2-dihydroquinoline-1-acetamide and its pharmaceutically acceptable salts, may be useful in the treatment of renal failure .
- the present invention therefore relates to the use of a quinoline-2 (1H) -one derivative of formula (I) or one of its pharmaceutically acceptable salts, and in particular 7-fluoro-2-oxo -4- [2- [4- (thieno [3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl] 1,2-dihydroquinoline-1-acetamide or one of its pharmaceutically salts acceptable, for the preparation of a medicament for the treatment of renal failure.
- Chronic renal failure results from a progressive and irreversible destruction of the nephrons, unlike the recovery capacity after acute renal damage. It involves a reduction in the glomerular filtration rate which takes place over several years. Whatever the cause, the reduction in nephron capital leads to a structural and functional hypertrophy of the remaining nephrons. This compensatory hypertrophy is linked to secondary hyperfiltration, due to the increase in glomerular capillary pressure and blood flow. Finally, this compensatory hypertrophy is deleterious because it predisposes to glomerular sclerosis, to an increase in the functional load of the less altered glomerules, leading in a second time to their destruction.
- Example 1 Study of the action of the active ingredient on diabetic nephropathy.
- Type I diabetes is induced in 90 male CD rats 220-250 g (C. River) by ip injection of streptozotocin at a dose of 65 mg / kg. Animals are considered diabetic when their blood sugar is higher than 3.5 mg / ml 48 hours after the injection. Batches and treatments
- the rats are divided into 4 lots: - 1 non-diabetic control lot + vehicle (water 5 ml / kg p.o.),
- mesangial activation evaluated by the expression of smooth muscle ⁇ -actin (immunohistochemistry), is significantly reduced (-49%, p ⁇ 0.05) by the active ingredient.
- the active ingredient (1 mg / kg / d po) reduces diabetic proteinuria from 13.1 ⁇ 3.4 mg / 100 g / 24 hours to 7.0 ⁇ 1.7 mg / 100 g / 24 hours compared to enalapril (5 mg / kg / d po) which brings it down to 7.3 ⁇ 1.2 mg / 100 g / 24 hours.
- the active ingredient (1 mg / kg / d po) significantly limits the increase in the mesangial area (-25%, p ⁇ 0.05), similarly to enalapril (5 mg / kg / d in)
- Example 2 oral formulation.
- Active release capsules of 10 mg to 200 mg
- the active ingredient and the first 4 excipients are sieved (630 ⁇ m grid), then mixed in a granulator mixer. The powder is then wetted with
- the excipients of the external phase (colloidal silica and magnesium stearate) are sieved (630 ⁇ m grid) and added to the granule, in a mixer type Turbula ® , and mixed for 10 minutes. The granule is then divided into size 0 capsules.
- Granules with a higher dosage of active ingredient can be formulated by replacing lactose with active ingredient.
- the capsules can be filled up to 400 mg.
- 7-fluoro-2-oxo-4- [2- [4- (thieno [3,2-c] pyridin-4-yl) piperazin-1-yl] ethyl] 1,2 -dihydroquinoline-1-acetamide and its pharmaceutically acceptable salts can be used for the manufacture of medicaments intended for the treatment of renal insufficiency.
- renal insufficiency covers in particular diabetic nephropathies.
- the quinoline-2 (1 / - /) - one derivatives of formula (I) or their pharmaceutically acceptable salts, and in particular 7-fluoro-2-oxo-4- [2- [4- (thieno [3, 2-c] pyridin-4-yl) piperazin-1-yl] ethyl] 1,2-dihydroquinoline-1-acetamide or its pharmaceutically acceptable salts, may also be useful in the manufacture of a medicament for the treatment of glomerulonephritis or still lupus nephropathies.
- the quinoline-2 (1H) -one derivatives of formula (I) or their pharmaceutically acceptable salts may be presented in any pharmaceutical form suitable for oral or parenteral administration, in combination with suitable excipients to allow daily administration of 10 to 200 mg per day as active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001279933A AU2001279933A1 (en) | 2000-08-01 | 2001-07-31 | Use of quinoline-2(1h)-one derivatives for treating renal disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0010136A FR2812548B1 (fr) | 2000-08-01 | 2000-08-01 | Utilisation de derives de quinolein-2(1h)-one ou un de leurs sels pharmaceutiquement acceptable pour la preparation d'un medicament destine au traitement de l'insuffisance renale |
FR00/10136 | 2000-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002009712A1 true WO2002009712A1 (fr) | 2002-02-07 |
Family
ID=8853192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/002493 WO2002009712A1 (fr) | 2000-08-01 | 2001-07-31 | Utilisation de derives de quinolein-2(1h)-one pour le traitement de l'insuffisance renale |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2001279933A1 (fr) |
FR (1) | FR2812548B1 (fr) |
WO (1) | WO2002009712A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008274A (en) * | 1986-04-02 | 1991-04-16 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and pharmaceutical composition for inhibiting adhesion of thrombocytes |
US5637597A (en) * | 1993-10-21 | 1997-06-10 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives for inhibiting production of interleukin-8 |
EP0850235A1 (fr) * | 1995-09-15 | 1998-07-01 | Synthelabo | Derives de quinolein-2(1h)-one comme antagonistes de la serotonine |
-
2000
- 2000-08-01 FR FR0010136A patent/FR2812548B1/fr not_active Expired - Fee Related
-
2001
- 2001-07-31 AU AU2001279933A patent/AU2001279933A1/en not_active Abandoned
- 2001-07-31 WO PCT/FR2001/002493 patent/WO2002009712A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5008274A (en) * | 1986-04-02 | 1991-04-16 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and salts thereof and pharmaceutical composition for inhibiting adhesion of thrombocytes |
US5637597A (en) * | 1993-10-21 | 1997-06-10 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives for inhibiting production of interleukin-8 |
EP0850235A1 (fr) * | 1995-09-15 | 1998-07-01 | Synthelabo | Derives de quinolein-2(1h)-one comme antagonistes de la serotonine |
Non-Patent Citations (1)
Title |
---|
BERRY ET AL.: "Antiplatelet and antithrombotic activity of SL 65.0472", BR. J. PHARMACOL., vol. 129, no. proc. suppl., January 2000 (2000-01-01), pages 57p, XP001002881 * |
Also Published As
Publication number | Publication date |
---|---|
FR2812548B1 (fr) | 2002-09-20 |
AU2001279933A1 (en) | 2002-02-13 |
FR2812548A1 (fr) | 2002-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR19980064024A (ko) | 약학 조성물 | |
JP3305315B2 (ja) | 動物及び人間の疼痛及び/又は炎症の抑制時における薬剤ならびにその製造及びその使用 | |
US6355661B1 (en) | Methods for treatment of sickle cell anemia | |
EP1108424B1 (fr) | Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale | |
JP2011513372A (ja) | レベチラセタムを含む医薬組成物 | |
JP2022058446A (ja) | L-オルニチンフェニルアセテート製剤 | |
JP2022525202A (ja) | 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と1日あたりの投薬量 | |
CN113242736A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法 | |
JPS6253932A (ja) | 血管拡張および抗無酸素症剤 | |
KR100736024B1 (ko) | 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 | |
JP2008546782A (ja) | 水溶性鎮痛剤およびその製造方法 | |
WO2002009712A1 (fr) | Utilisation de derives de quinolein-2(1h)-one pour le traitement de l'insuffisance renale | |
JPH0656669A (ja) | 活性酸素消去作用を持つプテリン誘導体製剤 | |
EP2157089B1 (fr) | Utilisations thérapeutiques de dérivés d'acide imidazol-5-carboxylique. | |
CN1052305A (zh) | 新吡啶衍生物、含它们的药物组合物及其制备方法 | |
CA2147762A1 (fr) | Agent soulageant les troubles circulatoires | |
JP2710633B2 (ja) | 心臓疾患治療剤 | |
FR2832633A1 (fr) | Composition pharmaceutique comprenant une association metformine et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete | |
JPH0588684B2 (fr) | ||
KR100479367B1 (ko) | 이트라코나졸을 포함하는 경구투여용 항진균제 조성물 | |
TW201206431A (en) | Association of xanthine oxidase inhibitors and metformin and use thereof | |
EP0412877A1 (fr) | Nouvelle forme galénique orale améliorant la biodisponibilité | |
EP0935964A1 (fr) | Compositions pharmaceutiques contenant des anti-inflammatoires non steroidiens et de la piperine | |
JP2004026813A (ja) | 医薬組成物 | |
FR2771005A1 (fr) | Nouvelle association pharmaceutique a activite analgesique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |